{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:37:53Z","timestamp":1791290273224,"version":"4.3.0"},"reference-count":207,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.intimp.2023.111192","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T15:00:17Z","timestamp":1699542017000},"page":"111192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"PB","title":["Multiple faces of multiple sclerosis in the era of highly efficient treatment modalities: Lymphopenia and switching treatment options challenges daily practice"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7712-7216","authenticated-orcid":false,"given":"Aigli G","family":"Vakrakou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Evgenia","family":"Brinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Alexaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Koumasopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panos","family":"Stathopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Eleftheria","family":"Evangelopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas","family":"Stefanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Stadelmann-Nessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinos","family":"Kilidireas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2023.111192_b0005","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis","volume":"76","author":"Harding","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0010","doi-asserted-by":"crossref","first-page":"e1041","DOI":"10.1212\/WNL.0000000000010135","article-title":"Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study","volume":"95","author":"Buron","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2023.111192_b0015","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1177\/1352458518768433","article-title":"Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis","volume":"24","author":"Lorscheider","year":"2018","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.intimp.2023.111192_b0020","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1177\/1352458516650736","article-title":"Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies","volume":"22","author":"Baroncini","year":"2016","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.intimp.2023.111192_b0025","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis","volume":"321","author":"Brown","year":"2019","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.intimp.2023.111192_b0030","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.868525","article-title":"Immunopathology of Tumefactive Demyelinating Lesions-From Idiopathic to Drug-Related Cases","volume":"13","author":"Vakrakou","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0035","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41591-019-0521-4","article-title":"GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis","volume":"25","author":"Galli","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2023.111192_b0040","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s40478-020-01010-8","article-title":"Single-cell mass cytometry reveals complex myeloid cell composition in active lesions of progressive multiple sclerosis","volume":"8","author":"B\u00f6ttcher","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.intimp.2023.111192_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.653577","article-title":"Mass Cytometry Identifies Expansion of T-bet(+) B Cells and CD206(+) Monocytes in Early Multiple Sclerosis","volume":"12","author":"Couloume","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.111192_b0050","doi-asserted-by":"crossref","unstructured":"D. Johansson, C. Rauld, J. Roux, C. Regairaz, E. Galli, I. Callegari et al. Mass Cytometry of CSF Identifies an MS-Associated B-cell Population. Neurology(R) neuroimmunology & neuroinflammation, 2021;8.","DOI":"10.1212\/NXI.0000000000000943"},{"key":"10.1016\/j.intimp.2023.111192_b0055","first-page":"106","article-title":"Regulation of experimental autoimmune encephalomyelitis (EAE) by CD4+CD25+ regulatory T cells","volume":"discussion -4","author":"Kohm","year":"200325245","journal-title":"Novartis Found. Symp."},{"key":"10.1016\/j.intimp.2023.111192_b0060","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1084\/jem.20031579","article-title":"Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis","volume":"199","author":"Viglietta","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2023.111192_b0065","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2567.2007.02690.x","article-title":"Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level","volume":"123","author":"Venken","year":"2008","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2023.111192_b0070","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nm.2389","article-title":"Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease","volume":"17","author":"Dominguez-Villar","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2023.111192_b0075","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/s41590-018-0236-6","article-title":"Activated \u03b2-catenin in Foxp3(+) regulatory T cells links inflammatory environments to autoimmunity","volume":"19","author":"Sumida","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2023.111192_b0080","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/135245859600100611","article-title":"A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis","volume":"1","author":"van Oosten","year":"1996","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.intimp.2023.111192_b0085","doi-asserted-by":"crossref","first-page":"10476","DOI":"10.1038\/s41598-021-88448-5","article-title":"Multiple sclerosis patients have reduced resting and increased activated CD4(+)CD25(+)FOXP3(+)T regulatory cells","volume":"11","author":"Verma","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2023.111192_b0090","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.clim.2014.03.005","article-title":"Disease exacerbation of multiple sclerosis is characterized by loss of terminally differentiated autoregulatory CD8+ T cells","volume":"152","author":"Cunnusamy","year":"2014","journal-title":"Clinical immunology (Orlando, Fla)"},{"key":"10.1016\/j.intimp.2023.111192_b0095","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1177\/1352458513509703","article-title":"HLA-E restricted CD8+ T cell subsets are phenotypically altered in multiple sclerosis patients","volume":"20","author":"Pannemans","year":"2014","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.intimp.2023.111192_b0100","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jaut.2010.12.003","article-title":"Neuroantigen-specific CD8+ regulatory T-cell function is deficient during acute exacerbation of multiple sclerosis","volume":"36","author":"Baughman","year":"2011","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2023.111192_b0105","doi-asserted-by":"crossref","unstructured":"S. Knippenberg, E. Peelen, J. Smolders, M. Thewissen, P. Menheere, J. W. Cohen Tervaert et al. Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced na\u00efve\/memory Breg ratio during a relapse but not in remission. Journal of neuroimmunology, 2011;239:80-6.","DOI":"10.1016\/j.jneuroim.2011.08.019"},{"key":"10.1016\/j.intimp.2023.111192_b0110","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.1523\/JNEUROSCI.2840-19.2020","article-title":"Regulatory B Cells Normalize CNS Myeloid Cell Content in a Mouse Model of Multiple Sclerosis and Promote Oligodendrogenesis and Remyelination","volume":"40","author":"Pennati","year":"2020","journal-title":"J. Neurosci."},{"issue":"196","key":"10.1016\/j.intimp.2023.111192_b0115","first-page":"1558","article-title":"Pivotal Role for CD16+ Monocytes in Immune Surveillance of the Central Nervous System","volume":"2016","author":"Waschbisch","year":"1950","journal-title":"J. Immunol. (Baltimore, Md"},{"key":"10.1016\/j.intimp.2023.111192_b0120","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/icb.2014.15","article-title":"Expansion and preferential activation of the CD14(+)CD16(+) monocyte subset during multiple sclerosis","volume":"92","author":"Chuluundorj","year":"2014","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.intimp.2023.111192_b0125","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1007\/s13311-021-01037-2","article-title":"Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study","volume":"18","author":"Zangh\u00ec","year":"2021","journal-title":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics"},{"key":"10.1016\/j.intimp.2023.111192_b0130","doi-asserted-by":"crossref","first-page":"1071623","DOI":"10.3389\/fimmu.2023.1071623","article-title":"Specific myeloid signatures in peripheral blood differentiate active and rare clinical phenotypes of multiple sclerosis","volume":"14","author":"Vakrakou","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.111192_b0135","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jneuroim.2016.10.007","article-title":"Myeloid dendritic cells exhibit defects in activation and function in patients with multiple sclerosis","volume":"301","author":"Haas","year":"2016","journal-title":"J. Neuroimmunol."},{"issue":"179","key":"10.1016\/j.intimp.2023.111192_b0140","first-page":"5228","article-title":"CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis","volume":"2007","author":"Zhu","year":"1950","journal-title":"Journal of immunology (Baltimore, Md"},{"key":"10.1016\/j.intimp.2023.111192_b0145","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jaut.2016.04.003","article-title":"Dysregulation of regulatory CD56(bright) NK cells\/T cells interactions in multiple sclerosis","volume":"72","author":"Laroni","year":"2016","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2023.111192_b0150","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3389\/fimmu.2016.00606","article-title":"Regulatory Functions of Natural Killer Cells in Multiple Sclerosis","volume":"7","author":"Gross","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.111192_b0155","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.immuni.2007.11.017","article-title":"S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress","volume":"28","author":"Pham","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2023.111192_b0160","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2023.111192_b0165","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.msard.2017.11.018","article-title":"Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod","volume":"19","author":"Fragoso","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.intimp.2023.111192_b0170","doi-asserted-by":"crossref","first-page":"e0124923","DOI":"10.1371\/journal.pone.0124923","article-title":"Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod","volume":"10","author":"Song","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2023.111192_b0175","doi-asserted-by":"crossref","first-page":"e0228380","DOI":"10.1371\/journal.pone.0228380","article-title":"Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets","volume":"15","author":"Hjorth","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2023.111192_b0180","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458517713147","article-title":"Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod","volume":"23","author":"Ghadiri","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.intimp.2023.111192_b0185","doi-asserted-by":"crossref","first-page":"35314","DOI":"10.1038\/srep35314","article-title":"Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy","volume":"6","author":"Fujii","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2023.111192_b0190","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/cns.12851","article-title":"Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients","volume":"24","author":"Quirant-S\u00e1nchez","year":"2018","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.intimp.2023.111192_b0195","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/cns.12548","article-title":"Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients","volume":"22","author":"Teniente-Serra","year":"2016","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.intimp.2023.111192_b0200","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.3389\/fimmu.2018.02669","article-title":"Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients","volume":"9","author":"Kaufmann","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.111192_b0205","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.3389\/fimmu.2018.01693","article-title":"Immunophenotype and Transcriptome Profile of Patients With Multiple Sclerosis Treated With Fingolimod: Setting Up a Model for Prediction of Response in a 2-Year Translational Study","volume":"9","author":"Moreno-Torres","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.111192_b0210","doi-asserted-by":"crossref","unstructured":"K. Okada, T. Hashimoto, M. Kobata, S. Kakeda, T. Takahashi, J. Hirato. Tumefactive demyelination with a transient appearance of oligoclonal bands in MS under fingolimod. Neurology(R) neuroimmunology & neuroinflammation, 2018;5:e484.","DOI":"10.1212\/NXI.0000000000000484"},{"key":"10.1016\/j.intimp.2023.111192_b0215","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3389\/fneur.2020.00782","article-title":"Case Report: A Case of Severe Clinical Deterioration in a Patient With Multiple Sclerosis","volume":"11","author":"Breitkopf","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0220","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.msard.2019.06.017","article-title":"Fulminant multifocal relapse in a fingolimod-treated multiple sclerosis patient","volume":"34","author":"Breville","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.intimp.2023.111192_b0225","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jns.2014.06.013","article-title":"Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy","volume":"344","author":"Hellmann","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.intimp.2023.111192_b0230","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1177\/1352458518763095","article-title":"Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation","volume":"24","author":"Giordana","year":"2018","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.intimp.2023.111192_b0235","article-title":"Tumefactive rebound of multiple sclerosis after the short-term cessation of fingolimod: A case report","volume":"39","author":"Ashtari","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.intimp.2023.111192_b0240","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ana.20858","article-title":"Immune surveillance in multiple sclerosis patients treated with natalizumab","volume":"59","author":"St\u00fcve","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0245","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/cei.12261","article-title":"Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab","volume":"176","author":"Koudriavtseva","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2023.111192_b0250","doi-asserted-by":"crossref","first-page":"e3319","DOI":"10.1371\/journal.pone.0003319","article-title":"Effects of natalizumab treatment on Foxp3+ T regulatory cells","volume":"3","author":"Stenner","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2023.111192_b0255","doi-asserted-by":"crossref","unstructured":"J. van Langelaar, R. M. van der Vuurst de Vries, M. Janssen, A. F. Wierenga-Wolf, I. M. Spilt, T. A. Siepman et al. T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention. Brain : a journal of neurology, 2018;141:1334-49.","DOI":"10.1093\/brain\/awy069"},{"key":"10.1016\/j.intimp.2023.111192_b0260","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1212\/WNL.0b013e3181a8266f","article-title":"Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells","volume":"72","author":"Kivis\u00e4kk","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2023.111192_b0265","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000302687","article-title":"Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells","volume":"63","author":"Putzki","year":"2010","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0270","doi-asserted-by":"crossref","unstructured":"C. Janoschka, M. Lindner, N. Koppers, L. Starost, M. Liebmann, M. Eschborn et al. Enhanced pathogenicity of Th17 cells due to natalizumab treatment: Implications for MS disease rebound. Proceedings of the National Academy of Sciences of the United States of America, 2023;120:e2209944120.","DOI":"10.1073\/pnas.2209944120"},{"key":"10.1016\/j.intimp.2023.111192_b0275","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1212\/01.wnl.0000327671.91357.96","article-title":"Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis","volume":"71","author":"Krumbholz","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2023.111192_b0280","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1177\/1352458514556296","article-title":"Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF","volume":"21","author":"Warnke","year":"2015","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.intimp.2023.111192_b0285","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1182\/blood-2007-10-120329","article-title":"The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans","volume":"111","author":"Zohren","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2023.111192_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102987","article-title":"Natalizumab differentially affects plasmablasts and B cells in multiple sclerosis","volume":"52","author":"Cuculiza Henriksen","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.intimp.2023.111192_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102470","article-title":"High effector-memory CD8(+) T-cell levels correlate with high PML risk in natalizumab-treated patients","volume":"46","author":"Beldi-Ferchiou","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.intimp.2023.111192_b0300","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1212\/WNL.0b013e3182840be3","article-title":"Fatal neuroinflammation in a case of multiple sclerosis with anti-natalizumab antibodies","volume":"80","author":"Svenningsson","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2023.111192_b0305","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1212\/WNL.0000000000002084","article-title":"Extensive brain demyelinating lesions under natalizumab: The role of anti-natalizumab antibodies","volume":"85","author":"Debs","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2023.111192_b0310","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jocn.2014.05.028","article-title":"Massive exacerbation of multiple sclerosis after withdrawal and early restart of treatment with natalizumab","volume":"22","author":"Beume","year":"2015","journal-title":"Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia"},{"key":"10.1016\/j.intimp.2023.111192_b0315","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1177\/1352458517703799","article-title":"Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS","volume":"24","author":"Fleischer","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.intimp.2023.111192_b0320","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1177\/1352458517717088","article-title":"Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile","volume":"24","author":"Medina","year":"2018","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.intimp.2023.111192_b0325","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1212\/CPJ.0000000000000567","article-title":"Lymphopenia and DMTs for relapsing forms of MS: Considerations for the treating neurologist","volume":"9","author":"Fox","year":"2019","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.intimp.2023.111192_b0330","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1212\/CPJ.0000000000000238","article-title":"Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerations","volume":"6","author":"Fox","year":"2016","journal-title":"Neurology Clinical practice"},{"key":"10.1016\/j.intimp.2023.111192_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103669","article-title":"Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis","volume":"59","author":"Sainz de la Maza","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.intimp.2023.111192_b0340","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1177\/1352458520937282","article-title":"Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity","volume":"27","author":"Longbrake","year":"2021","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.intimp.2023.111192_b0345","doi-asserted-by":"crossref","unstructured":"M. Diebold, E. Galli, A. Kopf, N. S. R. Sanderson, I. Callegari, P. Benkert et al. High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2022;119:e2205042119.","DOI":"10.1073\/pnas.2205042119"},{"key":"10.1016\/j.intimp.2023.111192_b0350","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/ana.26328","article-title":"Immunological Predictors of Dimethyl Fumarate-Induced Lymphopenia","volume":"91","author":"Diebold","year":"2022","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0355","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1212\/NXI.0000000000000177","article-title":"Low frequencies of central memory CD4 T cells in progressive multifocal leukoencephalopathy","volume":"2","author":"Dubois","year":"2015","journal-title":"Neurology(R) neuroimmunology & neuroinflammation"},{"key":"10.1016\/j.intimp.2023.111192_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103740","article-title":"Lymphopenia in Multiple Sclerosis patients treated with Ocrelizumab is associated with an effect on CD8 T cells","volume":"60","author":"Abbadessa","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.intimp.2023.111192_b0365","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.msard.2013.10.003","article-title":"Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica","volume":"3","author":"Graves","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.intimp.2023.111192_b0370","first-page":"9","article-title":"Ofatumumab Modulates Inflammatory T Cell Responses and Migratory Potential in Patients With Multiple Sclerosis","author":"von Essen","year":"2022","journal-title":"Neurology(R) neuroimmunology & neuroinflammation"},{"key":"10.1016\/j.intimp.2023.111192_b0375","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1007\/s00415-022-11197-6","article-title":"Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression","volume":"269","author":"Dorcet","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0380","doi-asserted-by":"crossref","unstructured":"K. Shinoda, R. Li, A. Rezk, I. Mexhitaj, K. R. Patterson, M. Kakara et al. Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity. Proceedings of the National Academy of Sciences of the United States of America, 2023;120:e2207291120.","DOI":"10.1073\/pnas.2207291120"},{"key":"10.1016\/j.intimp.2023.111192_b0385","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/intimm\/dxv038","article-title":"The expanding family of regulatory B cells","volume":"27","author":"Mauri","year":"2015","journal-title":"Int. Immunol."},{"key":"10.1016\/j.intimp.2023.111192_b0390","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.4049\/jimmunol.1502448","article-title":"Age-Associated B Cells with Proinflammatory Characteristics Are Expanded in a Proportion of Multiple Sclerosis Patients","volume":"197","author":"Claes","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2023.111192_b0395","first-page":"6","article-title":"Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab","author":"Moreira Ferreira","year":"2019","journal-title":"Neurology(R) neuroimmunology & neuroinflammation"},{"key":"10.1016\/j.intimp.2023.111192_b0400","article-title":"Immune Reconstitution Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: A Review on Behalf of the EBMT Autoimmune Diseases Working Party","volume":"12","author":"Cencioni","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.111192_b0405","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/1756285615601933","article-title":"The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects","volume":"9","author":"Sorensen","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.intimp.2023.111192_b0410","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.intimp.2023.111192_b0415","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1517\/14712598.2014.866084","article-title":"Current evaluation of alemtuzumab in multiple sclerosis","volume":"14","author":"Coyle","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.intimp.2023.111192_b0420","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12974-020-01847-9","article-title":"Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis","volume":"17","author":"Gilmore","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.intimp.2023.111192_b0425","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.intimp.2023.111192_b0430","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/jnnp-2011-300826","article-title":"Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis","volume":"83","author":"Hill-Cawthorne","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"191","key":"10.1016\/j.intimp.2023.111192_b0435","first-page":"5867","article-title":"Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis","volume":"2013","author":"Zhang","year":"1950","journal-title":"Journal of immunology (Baltimore, Md"},{"key":"10.1016\/j.intimp.2023.111192_b0440","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/imcb.12431","article-title":"Alemtuzumab mediates the CD39(+) T-regulatory cell response via CD23(+) macrophages","volume":"99","author":"Remez","year":"2021","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.intimp.2023.111192_b0445","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/imm.12879","article-title":"Alemtuzumab depletion failure can occur in multiple sclerosis","volume":"154","author":"Dubuisson","year":"2018","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2023.111192_b0450","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","article-title":"Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab","volume":"74","author":"Baker","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0455","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ebiom.2017.01.042","article-title":"Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis","volume":"16","author":"Baker","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.intimp.2023.111192_b0460","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/13524585211012227","article-title":"Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres","volume":"28","author":"Pfeuffer","year":"2022","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.intimp.2023.111192_b0465","first-page":"10","article-title":"Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS Substudy","author":"Wiendl","year":"2023","journal-title":"Neurology(R) neuroimmunology & neuroinflammation"},{"key":"10.1016\/j.intimp.2023.111192_b0470","doi-asserted-by":"crossref","first-page":"20200","DOI":"10.1073\/pnas.1313654110","article-title":"Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation","volume":"110","author":"Jones","year":"2013","journal-title":"PNAS"},{"key":"10.1016\/j.intimp.2023.111192_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577759","article-title":"IgG4-related autoimmune manifestations in Alemtuzumab-treated multiple sclerosis patients","volume":"361","author":"Vakrakou","year":"2021","journal-title":"J. Neuroimmunol."},{"issue":"198","key":"10.1016\/j.intimp.2023.111192_b0480","first-page":"2534","article-title":"Two Strikes and You're Out? The Pathogenic Interplay of Coinhibitor Deficiency and Lymphopenia-Induced Proliferation","volume":"2017","author":"Ellestad","year":"1950","journal-title":"Journal of immunology (Baltimore, Md"},{"key":"10.1016\/j.intimp.2023.111192_b0485","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/brain\/awac064","article-title":"Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity","volume":"145","author":"Ruck","year":"2022","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0490","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1007\/s00415-022-11300-x","article-title":"Innovative biomarkers to predict unfavourable outcomes after initiating multiple sclerosis treatment","volume":"269","author":"Kreft","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0495","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.760546","article-title":"Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab","volume":"12","author":"Walo-Delgado","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.111192_b0500","doi-asserted-by":"crossref","first-page":"e1926","DOI":"10.1212\/WNL.0000000000201029","article-title":"Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis","volume":"99","author":"Roos","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2023.111192_b0505","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40120-015-0038-9","article-title":"Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers","volume":"4","author":"Lo Re","year":"2015","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.intimp.2023.111192_b0510","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1177\/1352458520938354","article-title":"Tumefactive multiple sclerosis in association with fingolimod initiation and discontinuation","volume":"27","author":"Croteau","year":"2021","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.intimp.2023.111192_b0515","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.msard.2017.04.003","article-title":"Tumefactive demyelinating lesions: A comprehensive review","volume":"14","author":"Algahtani","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.intimp.2023.111192_b0520","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s13760-018-0948-2","article-title":"Tumefactive demyelinating lesions in a patient with multiple sclerosis receiving natalizumab","volume":"119","author":"Moghadasi","year":"2019","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.intimp.2023.111192_b0525","article-title":"A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo","volume":"3","author":"Vermersch","year":"2017","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"10.1016\/j.intimp.2023.111192_b0530","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s40261-019-00804-6","article-title":"Severe Exacerbation of Multiple Sclerosis Following Withdrawal of Fingolimod","volume":"39","author":"Fragoso","year":"2019","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.intimp.2023.111192_b0535","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/ene.13694","article-title":"Clinical activity after fingolimod cessation: disease reactivation or rebound?","volume":"25","author":"Frau","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103278","article-title":"Factors associated with fingolimod rebound: A single center real-life experience","volume":"56","author":"Goncuoglu","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.intimp.2023.111192_b0545","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jamaneurol.2016.0826","article-title":"Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment","volume":"73","author":"Hatcher","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0550","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2022-329607","article-title":"Rebound of clinical disease activity after fingolimod discontinuation? A nationwide cohort study of patients in Denmark","author":"Framke","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.intimp.2023.111192_b0555","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s00415-021-10658-8","article-title":"What happens after fingolimod discontinuation? A multicentre real-life experience","volume":"269","author":"Landi","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0560","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/cns.12992","article-title":"Frequency and clinical characteristics of Multiple Sclerosis rebounds after withdrawal of Fingolimod","volume":"24","author":"Evangelopoulos","year":"2018","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.intimp.2023.111192_b0565","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1007\/s13311-021-01106-6","article-title":"Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients","volume":"18","author":"Bianco","year":"2021","journal-title":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics"},{"key":"10.1016\/j.intimp.2023.111192_b0570","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jneuroim.2015.03.022","article-title":"Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation","volume":"282","author":"Berger","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.intimp.2023.111192_b0575","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.785180","article-title":"Case Report: Persisting Lymphopenia During Neuropsychiatric Tumefactive Multiple Sclerosis Rebound Upon Fingolimod Withdrawal","volume":"12","author":"Koska","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0580","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211006503","article-title":"Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases","volume":"14","author":"Vakrakou","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.intimp.2023.111192_b0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101483","article-title":"Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: Analysis of predisposing factors","volume":"38","author":"Sep\u00falveda","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.intimp.2023.111192_b0590","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1001\/archneurol.2011.1057","article-title":"Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment","volume":"69","author":"Havla","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0595","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/0022034511399915","article-title":"Immune reconstitution inflammatory syndrome","volume":"23","author":"Tappuni","year":"2011","journal-title":"Adv. Dent. Res."},{"key":"10.1016\/j.intimp.2023.111192_b0600","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbi.2015.06.019","article-title":"Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound","volume":"50","author":"Cavone","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.intimp.2023.111192_b0605","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1248\/bpb.34.933","article-title":"Relapse of experimental autoimmune encephalomyelitis after discontinuation of FTY720 (Fingolimod) treatment, but not after combination of FTY720 and pathogenic autoantigen","volume":"34","author":"Yoshida","year":"2011","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.intimp.2023.111192_b0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101927","article-title":"Rebound of disease activity after fingolimod withdrawal: Immunological and gene expression profiling","volume":"40","author":"Sacco","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.intimp.2023.111192_b0615","first-page":"18","article-title":"Natalizumab in Multiple Sclerosis: Long-Term Management","author":"Clerico","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2023.111192_b0620","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419837809","article-title":"Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis","volume":"12","author":"Prosperini","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.intimp.2023.111192_b0625","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s00415-014-7325-8","article-title":"Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients","volume":"261","author":"Sorensen","year":"2014","journal-title":"J. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0630","doi-asserted-by":"crossref","first-page":"e00671","DOI":"10.1002\/brb3.671","article-title":"Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation","volume":"7","author":"Gonz\u00e1lez-Suarez","year":"2017","journal-title":"Brain and behavior"},{"key":"10.1016\/j.intimp.2023.111192_b0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2019.105390","article-title":"A multicenter, non-interventional study to evaluate the disease activity in Multiple Sclerosis after withdrawal of Natalizumab in Portugal","volume":"184","author":"Ladeira","year":"2019","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.intimp.2023.111192_b0640","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.22163","article-title":"Natalizumab dosage suspension: are we helping or hurting?","volume":"68","author":"West","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0645","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s00415-011-5996-y","article-title":"De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate","volume":"258","author":"Havla","year":"2011","journal-title":"J. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0650","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1177\/1352458514549401","article-title":"Significant clinical worsening after natalizumab withdrawal: Predictive factors","volume":"21","author":"Vidal-Jordana","year":"2015","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.intimp.2023.111192_b0655","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00415-014-7574-6","article-title":"Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: a case report","volume":"262","author":"Sep\u00falveda","year":"2015","journal-title":"J. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0660","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/archneurol.2010.257","article-title":"Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy","volume":"68","author":"Miravalle","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0665","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1586\/14737175.2016.1168295","article-title":"Disease activity return after natalizumab cessation in multiple sclerosis","volume":"16","author":"Rasenack","year":"2016","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.intimp.2023.111192_b0670","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1352458516641775","article-title":"Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal","volume":"23","author":"Larochelle","year":"2017","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.intimp.2023.111192_b0675","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40120-019-00160-9","article-title":"Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations","volume":"8","author":"Barry","year":"2019","journal-title":"Neurol Ther"},{"key":"10.1016\/j.intimp.2023.111192_b0680","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419846818","article-title":"Severe rebound after cessation of fingolimod treated with ocrelizumab with coincidental transient aggravation: report of two cases","volume":"12","author":"Schmidt","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.intimp.2023.111192_b0685","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1080\/14786410500441664","article-title":"Rituximab therapy in monoclonal IgM-related neuropathies","volume":"47","author":"Kilidireas","year":"2006","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.intimp.2023.111192_b0690","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/WCO.0b013e328346be57","article-title":"Immune reconstitution inflammatory syndrome and the central nervous system","volume":"24","author":"Johnson","year":"2011","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0695","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/WCO.0000000000000200","article-title":"Neurological immune reconstitution inflammatory response: riding the tide of immune recovery","volume":"28","author":"Clifford","year":"2015","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0700","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00401-011-0900-5","article-title":"Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy","volume":"123","author":"Metz","year":"2012","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.intimp.2023.111192_b0705","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/ni.2018","article-title":"Normal T cell homeostasis: the conversion of naive cells into memory-phenotype cells","volume":"12","author":"Sprent","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2023.111192_b0710","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.4049\/jimmunol.177.7.4521","article-title":"Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection","volume":"177","author":"Brown","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2023.111192_b0715","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0092-8674(04)00335-6","article-title":"Homeostatic expansion of T cells during immune insufficiency generates autoimmunity","volume":"117","author":"King","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2023.111192_b0720","doi-asserted-by":"crossref","first-page":"8732","DOI":"10.1073\/pnas.161126098","article-title":"IL-7 is critical for homeostatic proliferation and survival of naive T cells","volume":"98","author":"Tan","year":"2001","journal-title":"PNAS"},{"key":"10.1016\/j.intimp.2023.111192_b0725","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/80868","article-title":"Interleukin-7 mediates the homeostasis of na\u00efve and memory CD8 T cells in vivo","volume":"1","author":"Schluns","year":"2000","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2023.111192_b0730","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.4049\/jimmunol.174.6.3158","article-title":"Recent immune status determines the source of antigens that drive homeostatic T cell expansion","volume":"174","author":"Kieper","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2023.111192_b0735","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","article-title":"Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy","volume":"380","author":"Cortese","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.111192_b0740","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/jnnp-2017-316886","article-title":"Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS","volume":"89","author":"Wattjes","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.intimp.2023.111192_b0745","doi-asserted-by":"crossref","first-page":"65","DOI":"10.14740\/jocmr1888w","article-title":"Immune reconstitution inflammatory syndrome mimicking progressive multifocal leucoencephalopathy in a multiple sclerosis patient treated with natalizumab: a case report and review of the literature","volume":"7","author":"Evangelopoulos","year":"2015","journal-title":"J. Clin. Med. Res."},{"key":"10.1016\/j.intimp.2023.111192_b0750","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1749-6632.2009.05111.x","article-title":"Neurological complications of immune reconstitution in HIV-infected populations","volume":"1184","author":"Johnson","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.intimp.2023.111192_b0755","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1086\/595006","article-title":"HIV\/AIDS: immune reconstitution inflammatory syndrome: a reappraisal","volume":"48","author":"French","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.intimp.2023.111192_b0760","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1080\/13550280802304753","article-title":"Progressive tumefactive inflammatory central nervous system demyelinating disease in an acquired immunodeficiency syndrome patient treated with highly active antiretroviral therapy","volume":"14","author":"Lindzen","year":"2008","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.intimp.2023.111192_b0765","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/1752-1947-4-214","article-title":"Severe leukoencephalopathy with fulminant cerebral edema reflecting immune reconstitution inflammatory syndrome during HIV infection: a case report","volume":"4","author":"Oelschlaeger","year":"2010","journal-title":"J Med Case Reports"},{"key":"10.1016\/j.intimp.2023.111192_b0770","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jneuroim.2018.03.011","article-title":"Epstein-Barr virus-associated immune reconstitution inflammatory syndrome as possible cause of fulminant multiple sclerosis relapse after natalizumab interruption","volume":"319","author":"Serafini","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.intimp.2023.111192_b0775","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1016\/j.msard.2017.06.005","article-title":"The 'Field Hypothesis': rebound activity after stopping disease-modifying therapies","volume":"15","author":"Giovannoni","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.intimp.2023.111192_b0780","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s13311-020-00975-7","article-title":"Differential Effects of Fingolimod and Natalizumab on B Cell Repertoires in Multiple Sclerosis Patients","volume":"18","author":"Kowarik","year":"2021","journal-title":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics"},{"key":"10.1016\/j.intimp.2023.111192_b0785","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12883-015-0354-9","article-title":"Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)","volume":"15","author":"Klotz","year":"2015","journal-title":"BMC Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0790","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.msard.2018.08.006","article-title":"Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab","volume":"25","author":"Bernard-Valnet","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.intimp.2023.111192_b0795","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1136\/jnnp-2020-325304","article-title":"Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab","volume":"92","author":"Pfeuffer","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.intimp.2023.111192_b0800","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/13524585211005657","article-title":"Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy","volume":"28","author":"Signoriello","year":"2022","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.intimp.2023.111192_b0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102981","article-title":"Challenges of switching towards anti-CD20 monoclonal antibodies in RR-MS: A monocentric study","volume":"52","author":"Boudot de la Motte","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.intimp.2023.111192_b0810","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00415-021-10708-1","article-title":"Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration","volume":"269","author":"Ferraro","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103076","article-title":"How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP)","volume":"53","author":"Bigaut","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.intimp.2023.111192_b0820","article-title":"Transitioning From S1P Receptor Modulators to B Cell-Depleting Therapies in Multiple Sclerosis: Clinical, Radiographic, and Laboratory Data","author":"Rowles","year":"20229","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.intimp.2023.111192_b0825","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.msard.2015.04.006","article-title":"Is it time to target no evident disease activity (NEDA) in multiple sclerosis?","volume":"4","author":"Giovannoni","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.intimp.2023.111192_b0830","doi-asserted-by":"crossref","unstructured":"M. Willis, O. Pearson, Z. Illes, T. Sejbaek, C. Nielsen, M. Duddy et al. An observational study of alemtuzumab following fingolimod for multiple sclerosis. Neurology(R) neuroimmunology & neuroinflammation, 2017;4:e320.","DOI":"10.1212\/NXI.0000000000000320"},{"key":"10.1016\/j.intimp.2023.111192_b0835","article-title":"Therapeutic Advances in Multiple Sclerosis","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103812","article-title":"Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis","volume":"62","author":"Nygaard","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.intimp.2023.111192_b0845","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/13524585221111677","article-title":"Prediction of relapse activity when switching to cladribine for multiple sclerosis","volume":"29","author":"Zhong","year":"2023","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.intimp.2023.111192_b0850","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1093\/brain\/awv260","article-title":"Fingolimod versus interferon beta\/glatiramer acetate after natalizumab suspension in multiple sclerosis","volume":"138","author":"Iaffaldano","year":"2015","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0855","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1001\/jamaneurol.2013.6240","article-title":"Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study","volume":"71","author":"Cohen","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0860","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1177\/1352458517726381","article-title":"Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients","volume":"24","author":"Leurs","year":"2018","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.intimp.2023.111192_b0865","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116498","article-title":"Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up","volume":"407","author":"Vollmer","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.intimp.2023.111192_b0870","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1212\/WNL.0000000000001706","article-title":"Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS","volume":"85","author":"Kappos","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2023.111192_b0875","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.msard.2018.07.005","article-title":"Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis","volume":"25","author":"Naegelin","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.intimp.2023.111192_b0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101498","article-title":"Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation","volume":"38","author":"Mustonen","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.intimp.2023.111192_b0885","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3109\/00207454.2015.1127919","article-title":"Pulsed corticosteroid treatment in MS patients stabilizes disease activity following natalizumab withdrawal prior to switching to fingolimod","volume":"126","author":"Evangelopoulos","year":"2016","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.intimp.2023.111192_b0890","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1468-1331.2011.03577.x","article-title":"Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study","volume":"19","author":"Borriello","year":"2012","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0895","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s00415-011-6019-8","article-title":"Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study","volume":"258","author":"Magraner","year":"2011","journal-title":"J. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0900","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00415-018-9117-z","article-title":"Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation","volume":"266","author":"Pfeuffer","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0905","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/practneurol-2015-001355","article-title":"Switching patients at high risk of PML from natalizumab to another disease-modifying therapy","volume":"16","author":"Giovannoni","year":"2016","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0910","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12974-019-1593-2","article-title":"Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients","volume":"16","author":"Traub","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.intimp.2023.111192_b0915","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ana.24651","article-title":"Rituximab versus fingolimod after natalizumab in multiple sclerosis patients","volume":"79","author":"Alping","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b0920","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1212\/CON.0000000000000738","article-title":"Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies","volume":"25","author":"Gross","year":"2019","journal-title":"Continuum (Minneapolis, Minn)"},{"key":"10.1016\/j.intimp.2023.111192_b0925","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1177\/1352458520946017","article-title":"Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab","volume":"27","author":"Mancinelli","year":"2021","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.intimp.2023.111192_b0930","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1177\/1352458520927631","article-title":"Switching from natalizumab to ocrelizumab in patients with multiple sclerosis","volume":"26","author":"Levin","year":"2020","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.intimp.2023.111192_b0935","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.3389\/fimmu.2019.01666","article-title":"Increased NK Cell Count in Multiple Sclerosis Patients Treated With Dimethyl Fumarate: A 2-Year Longitudinal Study","volume":"10","author":"Marastoni","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.111192_b0940","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/eji.201747277","article-title":"Dimethyl fumarate treatment alters NK cell function in multiple sclerosis","volume":"48","author":"Smith","year":"2018","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2023.111192_b0945","doi-asserted-by":"crossref","unstructured":"C. M. Spencer, E. C. Crabtree-Hartman, K. Lehmann-Horn, B. A. Cree, S. S. Zamvil. Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurology(R) neuroimmunology & neuroinflammation, 2015;2:e76.","DOI":"10.1212\/NXI.0000000000000076"},{"key":"10.1016\/j.intimp.2023.111192_b0950","doi-asserted-by":"crossref","unstructured":"C. C. Gross, A. Schulte-Mecklenbeck, S. Klinsing, A. Posevitz-Fejf\u00e1r, H. Wiendl, L. Klotz. Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis. Neurology(R) neuroimmunology & neuroinflammation, 2016;3:e183.","DOI":"10.1212\/NXI.0000000000000183"},{"key":"10.1016\/j.intimp.2023.111192_b0955","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1177\/1352458515608961","article-title":"Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients","volume":"22","author":"Longbrake","year":"2016","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"issue":"198","key":"10.1016\/j.intimp.2023.111192_b0960","first-page":"3069","article-title":"Dimethyl Fumarate Selectively Reduces Memory T Cells and Shifts the Balance between Th1\/Th17 and Th2 in Multiple Sclerosis Patients","volume":"2017","author":"Wu","year":"1950","journal-title":"Journal of immunology (Baltimore, Md"},{"key":"10.1016\/j.intimp.2023.111192_b0965","article-title":"Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients","author":"Montes Diaz","year":"201888194","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2023.111192_b0970","doi-asserted-by":"crossref","unstructured":"T. W. Houston, Q. Howlett-Prieto, C. Regenauer, F. D. Testai, F. Yao, X. Feng et al. Increased Percentage of CD8(+)CD28(-) Regulatory T Cells With Fingolimod Therapy in Multiple Sclerosis. Neurology(R) neuroimmunology & neuroinflammation, 2023;10.","DOI":"10.1212\/NXI.0000000000200075"},{"key":"10.1016\/j.intimp.2023.111192_b0975","article-title":"Impact of treatment on cellular immunophenotype in MS: A cross-sectional study","volume":"7","author":"Cellerino","year":"2020","journal-title":"Neurology(R) neuroimmunology & neuroinflammation"},{"key":"10.1016\/j.intimp.2023.111192_b0980","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.3389\/fimmu.2018.01560","article-title":"Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of Non-T Cell Populations into the Cerebrospinal Fluid-Results from the ToFingo Successor Study","volume":"9","author":"Lohmann","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.111192_b0985","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1007\/s10072-021-05623-2","article-title":"Fingolimod as a first- or second-line treatment in a mini-series of young Hellenic patients with adolescent-onset multiple sclerosis: focus on immunological data","volume":"43","author":"Gontika","year":"2022","journal-title":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology"},{"key":"10.1016\/j.intimp.2023.111192_b0990","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.705618","article-title":"Decreased Neurofilament L Chain Levels in Cerebrospinal Fluid and Tolerogenic Plasmacytoid Dendritic Cells in Natalizumab-Treated Multiple Sclerosis Patients - Brief Research Report","volume":"15","author":"Moraes","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.intimp.2023.111192_b0995","doi-asserted-by":"crossref","first-page":"e0235449","DOI":"10.1371\/journal.pone.0235449","article-title":"Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-\u03b2, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab","volume":"15","author":"Kemmerer","year":"2020","journal-title":"PLoS One"},{"issue":"193","key":"10.1016\/j.intimp.2023.111192_b1000","first-page":"580","article-title":"Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients","volume":"2014","author":"Palanichamy","year":"1950","journal-title":"J. Immunol. (Baltimore, Md"},{"key":"10.1016\/j.intimp.2023.111192_b1005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4103\/1735-5362.343085","article-title":"Comparison of follicular T helper cells, monocytes, and T cells priming between newly diagnosed and rituximab-treated MS patients and healthy controls","volume":"17","author":"Yahyazadeh","year":"2022","journal-title":"Res. Pharm. Sci."},{"key":"10.1016\/j.intimp.2023.111192_b1010","article-title":"Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis","volume":"10","author":"Garcia","year":"2023","journal-title":"Neurol. (R) Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.intimp.2023.111192_b1015","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s00415-022-11350-1","article-title":"Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study","volume":"270","author":"Capasso","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b1020","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1177\/13524585211003301","article-title":"Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis","volume":"27","author":"Howlett-Prieto","year":"2021","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.intimp.2023.111192_b1025","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00415-018-8830-y","article-title":"Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells","volume":"265","author":"Ceronie","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.intimp.2023.111192_b1030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.563645","article-title":"Effects of Alemtuzumab on (Auto)antigen-Specific Immune Responses","volume":"11","author":"Hilger","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.111192_b1035","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1177\/1352458517741191","article-title":"Fulminant rebound of relapsing-remitting multiple sclerosis after discontinuation of dimethyl fumarate: A case report","volume":"24","author":"Harmel","year":"2018","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923015199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923015199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:05:56Z","timestamp":1761588356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923015199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":207,"alternative-id":["S1567576923015199"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.111192","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple faces of multiple sclerosis in the era of highly efficient treatment modalities: Lymphopenia and switching treatment options challenges daily practice","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.111192","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111192"}}